Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · IEX Real-Time Price · USD
5.51
+0.02 (0.36%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Ardelyx Revenue
Ardelyx had revenue of $159.11M in the twelve months ending March 31, 2024, with 152.32% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $46.02M with 304.81% year-over-year growth. In the year 2023, Ardelyx had annual revenue of $124.46M with 138.61% growth.
Revenue (ttm)
$159.11M
Revenue Growth
+152.32%
P/S Ratio
8.10
Revenue / Employee
$595,918
Employees
267
Market Cap
1.29B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
Dec 31, 2017 | 42.00M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
Dec 31, 2012 | 5.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Omnicell | 1.10B |
ANI Pharmaceuticals | 517.46M |
Arcus Biosciences | 237.00M |
Establishment Labs Holdings | 155.79M |
Gyre Therapeutics | 140.62M |
Prothena Corporation | 89.25M |
Immatics | 80.95M |
Ocular Therapeutix | 59.84M |
ARDX News
- 4 days ago - Ardelyx sues US health department over kidney disease drug - Reuters
- 4 days ago - Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines - GlobeNewsWire
- 19 days ago - ARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law Violations - GlobeNewsWire
- 19 days ago - To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA - GlobeNewsWire
- 23 days ago - Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines - GlobeNewsWire
- 7 weeks ago - Ardelyx, Inc. Reports Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults - GlobeNewsWire